Climb Bio Gets FDA Fast-Track Designation for Budoprutug in Rare Kidney Disease
By Colin Kellaher
Climb Bio has won the Food and Drug Administration's fast-track designation for its proposed budoprutug treatment for the rare kidney disease primary membranous nephropathy, or pMN.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
Climb Bio on Tuesday said there are currently no FDA-approved treatments for pMN, which affects about 75,000 people in the U.S. and can lead to chronic or end-stage kidney disease, requiring dialysis or transplantation.
The Wellesley Hills, Mass., clinical-stage biotechnology company, which is conducting a Phase 2 study of budoprutug in pMN, said it expects to share initial data from the study in the second half of 2026.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 07, 2026 07:39 ET (11:39 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States